Supha Pharmachem Ltd (REMLIFE) — shareholding pattern, promoter holding, financials and share price
About Supha Pharmachem Ltd (REMLIFE)
Supha Pharmachem Ltd operates in the Trading & Distributors industry, within the Services sector. It trades on the NSE as REMLIFE and on the BSE under scrip code 539561. Its ISIN is INE549S01036.
Incorporated in 1988, Remedium Lifecare Ltd is in the business of trading in Advanced Pharmaceutical Intermediates and other pharma products
Remedium Lifecare Limited is a pharmaceutical company specializing in trading and selling APIs and intermediates. They operate in both domestic and international markets, including regulated ones.
The company changed its name from 'Roxy Exports Limited' to 'Remedium Lifecare Limited' to reflect its updated business focus.
Listed peers in Trading & Distributors: Chandra Prabhu International Ltd, Chambal Breweries & Distilleries Ltd, Nirav Commercials Ltd, Ramgopal Polytex Ltd, Gini Silk Mills Ltd, AA Plus Tradelink Ltd.
Valuation & Returns
28 Jul 2026At ₹0.34 a share on 28 Jul 2026, Supha Pharmachem Ltd (REMLIFE) was valued at a price-to-earnings ratio of -65.68x against an industry P/E of 21.46x and a price-to-book of 0.69x on a book value of ₹0.49 per share as of Mar 2025. Solomo computes return on equity of -5.04% and return on capital employed of 0.08% from filed results. Earnings ratios use standalone results for the twelve months Dec 2024 to Sep 2025.
- P/E
- -65.68x
- Industry P/E
- 21.46x
- P/B
- 0.69x
- EPS (TTM)
- ₹-0.02
- Book value / share
- ₹0.49
- ROE
- -5.04%
- ROCE
- 0.08%
- ROA
- -0.14%
- Debt / equity
- 26.36x
- Dividend yield
- 0%
- 52-week range
- ₹0.25 – ₹1.8
Ratios are computed from filed results and the last recorded price. Not investment advice.
Financial Performance
Mar 2025In the year ended Mar 2025, Supha Pharmachem Ltd (REMLIFE) reported revenue of ₹405 crore, net profit of ₹2 crore and earnings per share of ₹0.02. Figures are consolidated, as filed with the exchanges.
In the quarter ended Sep 2025, revenue was ₹111.06 crore and net profit ₹8.62 crore (consolidated).
| Metric | Mar 2025 |
|---|---|
| Revenue (₹ cr) | 405 |
| Net profit (₹ cr) | 2 |
| EPS (₹) | 0.02 |
| Measure | 10Y | 5Y | 3Y | 1Y |
|---|---|---|---|---|
| Sales growth | 56.58% | 138.39% | -23.90% | -94.49% |
| Profit growth | 73.11% | 40.78% | 12.44% | -95.33% |
| Stock price CAGR | - | -37% | -86% | -73% |
Ownership Summary
Dec 2025As of Dec 2025, promoters hold 1.13% of Supha Pharmachem Ltd (REMLIFE) (unchanged from the previous quarter), foreign institutional investors (FII) hold 1.7%. Market capitalisation was ₹30 crore on 28 Jul 2026. Shareholding is filed quarterly with BSE and NSE; Solomo carries every filing back to Sep 2015.
Largest disclosed public shareholders in Dec 2025: UPPINANGADY SUDHINDRA NAYAK 3.2%, MANJU DEVI 2.46%, L7 HITECH PRIVATE LIMITED 2.34%, REMEDIUM ESCROW SUSPENSE ACCOUNT 2.2%, KAMAL ASNANI 2.19%, ZETA GLOBAL FUNDS (OEIC) PCC LIMITED-ZETA SERIES B FUND PC 1.7%. Only stakes above the 1% disclosure threshold are named in filings.
| Quarter | Promoter | Pledged | FII | DII | Public |
|---|---|---|---|---|---|
| Dec 2025 | 1.13% | - | 1.7% | - | 98.87% |
| Sep 2025 | 1.13% | - | - | - | 98.87% |
| Jun 2025 | 1.13% | - | - | - | 98.87% |
| Mar 2025 | 1.11% | - | - | - | 98.89% |
| Dec 2024 | 1.11% | - | - | - | 98.89% |
| Sep 2024 | 1.11% | - | - | - | 98.89% |
| Jun 2024 | 1.11% | - | - | - | 98.89% |
| Mar 2024 | 1.11% | - | 0.04% | - | 98.89% |